Last updated: September 7, 2026
Remimazolam besylate is a short-acting intravenous benzodiazepine marketed primarily as Byfavo for procedural sedation and general anesthesia. Its commercial profile is geographically fragmented: Jiangsu Hengrui dominates China, Mundipharma and regional partners cover several Asian and European markets, and Eagle Pharmaceuticals controls U.S. commercialization through its acquisition of Acacia Pharma.
The drug has regulatory approval in the United States, Japan, China, the European Union and other markets. Revenue growth depends on replacing midazolam in procedural sedation, expanding use in general anesthesia, securing hospital formulary access and overcoming entrenched competition from propofol, midazolam and dexmedetomidine. The product has a differentiated pharmacology, but its price premium and intravenous administration limit rapid conversion.
What is remimazolam besylate and how is it used?
Remimazolam besylate is an ultra-short-acting benzodiazepine administered intravenously. It produces sedation through activity at the gamma-aminobutyric acid type A receptor and can be reversed with flumazenil.
The principal commercial uses are:
- Procedural sedation for diagnostic or therapeutic procedures.
- Induction and maintenance of general anesthesia.
- Sedation in selected intensive-care and monitored-anesthesia settings, depending on local approval.
- Potential use in patients where rapid onset, rapid offset or reversibility is commercially valuable.
The U.S. product, Byfavo, is approved for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. The FDA approved Byfavo on July 1, 2020, based on clinical studies showing effective sedation with recovery characteristics that supported its use in monitored procedural settings (U.S. Food and Drug Administration, 2020).
China and Japan have broader commercial experience with remimazolam, including general anesthesia. This difference matters because the general-anesthesia market is substantially larger than short-duration procedural sedation, but it is also more price-sensitive and competitive.
Which companies market remimazolam besylate?
The commercial structure is regional rather than global.
| Market |
Commercial product or company |
Primary commercial role |
| United States |
Byfavo, Eagle Pharmaceuticals |
Procedural sedation |
| Japan |
Byfavo, Mundipharma and local partners |
General anesthesia and related hospital use |
| China |
Remimazolam besylate, Jiangsu Hengrui Pharmaceuticals |
Procedural sedation and general anesthesia |
| European Union |
Byfavo, PAION licensees and regional partners |
Procedural sedation and selected anesthesia use |
| South Korea |
Byfavo or local remimazolam products |
Procedural sedation and anesthesia |
| Other markets |
Licensees and distributors |
National approval and hospital commercialization |
Eagle Pharmaceuticals acquired Acacia Pharma in 2022. The transaction gave Eagle access to Byfavo and expanded its hospital-anesthesia portfolio (Eagle Pharmaceuticals, 2022). PAION retained or licensed rights in various territories, while Hengrui developed and commercialized its own Chinese product.
The resulting market has several competing commercial models:
- Direct commercialization by a regional originator or licensee.
- Local licensing to a hospital-focused pharmaceutical company.
- Domestic production and pricing in China.
- Distribution through anesthesia and specialty-care sales forces.
When did remimazolam besylate receive FDA approval?
The FDA approved Byfavo in 2020 for procedural sedation in adults. Its label specifies use by trained personnel in settings equipped to monitor respiration and cardiovascular function.
The approval established three commercial advantages:
- Rapid onset suitable for outpatient procedures.
- Short recovery profile relative to longer-acting benzodiazepines.
- Reversibility with flumazenil, a feature not shared by propofol.
The FDA indication is narrower than the approvals in Japan and China. U.S. expansion into general anesthesia would require additional regulatory work and clinical evidence. That limits the near-term U.S. addressable market to procedures such as endoscopy, bronchoscopy, cardioversion and selected interventional procedures.
How large is the remimazolam besylate market?
Remimazolam competes in a large but fragmented anesthesia and procedural-sedation market. The commercial opportunity is not equivalent to the total intravenous anesthetic market because hospitals select agents based on procedure length, workflow, recovery requirements, physician preference and reimbursement.
The main addressable segments are:
| Segment |
Commercial attractiveness |
Main barrier |
| Endoscopy sedation |
High |
Propofol and midazolam familiarity |
| Bronchoscopy |
High |
Established sedation protocols |
| Interventional cardiology |
Moderate to high |
Need for predictable recovery |
| General anesthesia |
High |
Low-cost propofol and established anesthetics |
| Intensive-care sedation |
Moderate |
Safety, staffing and reimbursement requirements |
| Emergency medicine |
Moderate |
Workflow and training requirements |
China offers the largest volume opportunity because of its population, high procedure growth and domestic pharmaceutical infrastructure. The United States offers higher pricing but a narrower approved indication and strong competitive pressure from generic agents.
Japan is strategically important because general-anesthesia adoption provides a commercial proof point for broader use. Europe offers a multi-country opportunity, but market access is slow and pricing is constrained by national reimbursement systems.
What is the financial trajectory for remimazolam besylate?
Public financial disclosure is divided among several companies, so no single consolidated global revenue figure is available. The financial trajectory has four distinct characteristics.
China is the principal volume market
Hengrui has the strongest position in China because it combines domestic regulatory access, hospital relationships, manufacturing scale and local pricing capability. Remimazolam sales benefit from broader indications than in the United States and from use across both procedural sedation and general anesthesia.
China is likely to remain the largest unit market. The main financial constraint is price erosion under centralized and volume-based procurement policies. China can produce substantial prescription volume without generating the same per-vial economics available in the United States or Japan.
Japan provides higher-value anesthesia utilization
Japan approved remimazolam for general anesthesia in 2020. The market has supported use beyond short outpatient procedures, improving the product's revenue potential per hospital account.
Mundipharma's commercialization model has focused on anesthesiology and hospital adoption. Revenue growth depends on demonstrating operational advantages over propofol and conventional benzodiazepines, particularly predictable emergence and the option of flumazenil reversal.
The U.S. launch has been commercially gradual
Byfavo entered the U.S. market through Acacia Pharma and later became part of Eagle Pharmaceuticals after the acquisition of Acacia. Commercial uptake has been slower than a broad primary-care launch because:
- The product is administered in hospitals and procedure centers.
- Anesthesiologists and gastroenterologists already use low-cost alternatives.
- Hospitals require formulary review and protocol integration.
- The approved indication is limited to procedures lasting 30 minutes or less.
- The product competes against generic midazolam and propofol.
U.S. revenue can support a specialty-hospital business, but a blockbuster trajectory requires either significant share capture in endoscopy or an expanded indication.
European revenue has been partner-dependent
PAION's European model relied on licensing and commercial partners. This reduced direct selling costs but also limited control over launch timing, inventory and hospital penetration. PAION's financial position deteriorated as commercial investment continued ahead of product scale. The company entered insolvency proceedings in 2024 after failing to secure sufficient financing, according to public company disclosures and insolvency announcements (PAION AG, 2024).
The insolvency created a restructuring risk for European rights, licensing arrangements and commercial continuity. It did not eliminate remimazolam's regulatory approvals or the product's value to regional partners.
How does remimazolam compare with propofol and midazolam?
| Attribute |
Remimazolam |
Propofol |
Midazolam |
| Onset |
Rapid |
Very rapid |
Slower |
| Recovery |
Short, with flumazenil reversal option |
Short, no specific reversal agent |
Longer and less predictable |
| Respiratory depression |
Present risk |
Present risk |
Present risk |
| Hypotension |
Generally less prominent than propofol in some studies |
Common clinical concern |
Usually less than propofol |
| Administration |
Intravenous |
Intravenous |
Intravenous or other routes |
| Cost |
Premium branded pricing |
Low generic pricing |
Low generic pricing |
| Main advantage |
Rapid offset and reversibility |
Low cost and clinician familiarity |
Familiarity and low cost |
| Main weakness |
Price and limited indications |
Cardiovascular and respiratory effects |
Variable recovery and prolonged sedation |
Clinical studies have generally positioned remimazolam as an effective alternative to propofol for procedural sedation, with a potentially favorable hemodynamic profile and rapid recovery. The economic question is whether those benefits reduce total procedure cost or improve throughput enough to offset the acquisition premium (Doi et al., 2021; Pastis et al., 2019).
What patents protect remimazolam besylate?
Remimazolam's intellectual-property protection includes composition-of-matter, formulation, manufacturing and method-of-use rights. The estate is geographically fragmented because different rights holders and licensees control different markets.
The practical protection profile is weaker than that of a newly launched biologic for three reasons:
- The active ingredient is a small molecule.
- Generic manufacturers can challenge patents through abbreviated regulatory pathways.
- Hospital buyers can substitute established intravenous sedatives without changing the overall treatment category.
In the United States, the key commercial question is not only the nominal patent expiration date. It is whether an Orange Book-listed patent remains enforceable and whether a generic applicant files a Paragraph IV certification.
The relevant patent categories are:
| Patent category |
Commercial relevance |
| Composition of matter |
Protects remimazolam chemical entity or salt |
| Formulation |
May protect injectable concentration, stability or excipient system |
| Manufacturing process |
Can raise cost and technical barriers for generic production |
| Method of sedation |
May protect procedural or anesthesia use |
| Dosing regimen |
Can limit label-based generic substitution if listed and enforceable |
The FDA Orange Book identifies patents and regulatory exclusivities associated with approved U.S. products. Its listing must be reviewed alongside the FDA label, patent-term-adjustment records and litigation docket because listed patents can expire at different times and may not all block the same commercial activities (U.S. Food and Drug Administration, 2024a).
When does remimazolam lose exclusivity?
The U.S. product's regulatory exclusivity is separate from its patent protection.
Byfavo received approval in 2020. A three-year period of marketing exclusivity associated with clinical investigations would have expired in 2023 if that exclusivity applied to the approved indication. Any remaining U.S. protection would therefore depend primarily on patents, pediatric exclusivity, patent-term adjustment or later-approved protected indications.
The likely generic-entry sequence is:
| Event |
Commercial effect |
| Patent and exclusivity review |
Determines whether an ANDA can be filed |
| Paragraph IV filing |
Creates litigation risk and possible 30-month stay |
| ANDA approval |
Does not necessarily permit immediate launch |
| Patent settlement |
Establishes a negotiated launch date |
| First generic launch |
Creates rapid price pressure in hospital accounts |
| Multiple generic entrants |
Accelerates price erosion |
A generic applicant could challenge composition, formulation, manufacturing or method-of-use patents. The most important litigation risk would arise from a Paragraph IV certification against a patent listed for the approved procedural-sedation indication.
Which companies are challenging remimazolam patents?
No single global Paragraph IV challenger has established a public, market-defining litigation position comparable to major generic disputes involving high-revenue drugs. Potential challengers include large injectable-generic manufacturers and specialized hospital-drug companies.
The likely challenger group includes manufacturers with:
- Sterile injectable production capacity.
- FDA-approved anesthesia or sedation products.
- Existing hospital distribution.
- Experience with ANDA litigation.
- Access to remimazolam active pharmaceutical ingredient or an equivalent synthesis route.
In China, competition is more likely to develop through domestic approvals, procurement pricing and local production than through U.S.-style patent litigation. In Europe, launch competition will depend on national patent status and local regulatory substitution rules.
What is the Orange Book status of Byfavo?
Byfavo is an FDA-approved small-molecule drug, so its U.S. patent and exclusivity position is assessed through the Orange Book and related FDA records. Orange Book status determines whether an ANDA applicant must certify against listed patents and whether a patent dispute can delay approval.
The commercial implications are:
- Orange Book-listed patents can generate a 30-month stay after qualifying litigation.
- Unlisted patents may still be enforceable but do not create the same automatic ANDA litigation mechanism.
- Method-of-use patents may be addressed through a section viii statement or labeling carve-out.
- A generic can receive approval with a restricted label if protected uses are omitted.
For investors and licensees, the central diligence issue is the gap between nominal patent expiration and practical generic launch. A patent may expire before meaningful generic entry if manufacturing complexity, low market size or limited injectable capacity reduces challenger interest.
What formulation and manufacturing barriers protect the product?
Remimazolam is supplied as an injectable product requiring sterile manufacturing, controlled formulation and hospital-ready packaging. Sterile injectable production creates a higher entry barrier than tablets, even after patent expiry.
Potential technical barriers include:
- Sterile fill-finish capacity.
- Stability of the drug product.
- Consistent reconstitution and concentration.
- Impurity control.
- Batch-to-batch potency.
- Compatibility with hospital preparation systems.
- Regulatory validation of the manufacturing process.
These barriers are meaningful but not permanent. Injectable generics have entered many mature hospital markets once demand is sufficient. The strongest protection exists where formulation patents overlap with difficult manufacturing steps and where the addressable market is too small to attract several entrants.
What licensing deals affect remimazolam besylate?
Remimazolam has been commercialized through multiple licensing and regional partnership arrangements.
The most important transaction was Eagle Pharmaceuticals' acquisition of Acacia Pharma in 2022. Acacia had commercial rights to Byfavo in the United States and marketed other hospital products. Eagle's acquisition added Byfavo to its specialty pharmaceutical portfolio (Eagle Pharmaceuticals, 2022).
PAION developed the product and entered regional licensing relationships for commercialization outside markets controlled directly by other partners. Hengrui's Chinese development and commercialization created a separate domestic commercial franchise. Mundipharma has been central to commercialization in Japan and selected international territories.
The licensing model creates both upside and risk:
- Upfront and milestone payments can finance development.
- Regional partners provide hospital sales infrastructure.
- Royalties reduce the originating company's net revenue.
- Multiple partners can produce inconsistent pricing and launch timing.
- Insolvency or ownership changes can disrupt regional rights.
What generic launch risks exist for remimazolam?
The most likely generic-launch risk is gradual erosion rather than an immediate global collapse.
United States
The risk is moderate in the near term and increases as patent barriers weaken. The narrow procedural-sedation label and sterile-injectable requirements may limit the first wave of entrants. A successful generic could pressure price and hospital formulary position quickly.
China
The risk is high for price erosion because domestic competition and procurement policies can reduce net selling prices even while unit volume grows. Hengrui's competitive advantage is scale and market access, not necessarily durable premium pricing.
Japan
The risk is moderate. General-anesthesia utilization can support demand, but Japanese reimbursement controls and potential local competition constrain pricing.
Europe
The risk is country-specific. Patent, reimbursement and substitution rules differ across markets. A lower-priced generic can gain share quickly where hospital procurement is centralized.
How strong is the remimazolam patent estate?
The patent estate is commercially useful but not unassailable.
Its strengths are:
- Multiple possible protection layers.
- Regulatory approvals across major markets.
- Manufacturing complexity associated with sterile injectable products.
- Clinical differentiation from midazolam and propofol.
- Potential method-of-use and dosing claims.
Its weaknesses are:
- Small-molecule exposure to generic competition.
- Narrow U.S. procedural-sedation indication.
- Existing low-cost alternatives.
- Fragmented ownership and licensing.
- Limited ability to maintain premium pricing in China and Europe.
- Lack of a single global commercial owner.
The estate is strongest as a launch and market-development tool. It is less likely to support long-duration premium pricing without additional indications or demonstrable hospital-economics benefits.
What is the competitive outlook for remimazolam?
The principal competitors are propofol, midazolam and dexmedetomidine. Propofol remains the reference competitor for rapid sedation and general anesthesia. Midazolam remains the low-cost benzodiazepine alternative. Dexmedetomidine competes in selected monitored-sedation settings but has a different pharmacologic and hemodynamic profile.
Remimazolam's best commercial positioning is in cases where clinicians value:
- Rapid recovery.
- Predictable titration.
- Reversal capability.
- Reduced hemodynamic disruption relative to propofol in selected patients.
- Standardized sedation protocols.
- High procedure throughput.
The product is less attractive where acquisition cost dominates and established generic agents provide acceptable outcomes.
What is the likely revenue trajectory?
The base-case financial trajectory is regional growth followed by price normalization.
| Period |
Likely commercial phase |
Revenue implication |
| 2020-2022 |
Regulatory approvals and initial launch |
Low base, high launch costs |
| 2023-2025 |
Hospital adoption and geographic expansion |
Growth led by China and Japan |
| 2025-2028 |
Broader competition and pricing pressure |
Volume growth with lower net price |
| After major patent expiry |
Generic and local competition |
Margin compression, possible unit expansion |
The upside case requires U.S. adoption in high-volume endoscopy, general-anesthesia expansion, successful European procurement access and continued Chinese volume growth.
The downside case involves slow formulary adoption, low physician switching, reimbursement pressure, U.S. patent litigation and loss of European commercial infrastructure after PAION's insolvency.
Key Takeaways
- Remimazolam besylate is a differentiated intravenous benzodiazepine with rapid onset, rapid recovery and flumazenil reversibility.
- China is likely to remain the largest volume market, while Japan provides the broadest anesthesia use case.
- The U.S. opportunity is commercially attractive but constrained by the narrow procedural-sedation indication.
- Eagle Pharmaceuticals is the key U.S. commercial company after acquiring Acacia Pharma.
- PAION's 2024 insolvency increased European licensing and commercialization risk.
- Propofol and generic midazolam are the main competitive threats.
- Patent protection is important but will not prevent long-term pressure from sterile-injectable generics and local Chinese competitors.
- The financial outlook is more consistent with a specialty hospital product than with a global blockbuster unless the label expands and hospital economics support premium pricing.
FAQs
Is remimazolam besylate a generic drug?
No. Remimazolam besylate is an innovative small-molecule anesthetic sold under branded products such as Byfavo. Generic versions may enter after applicable patents and regulatory exclusivities expire.
Is remimazolam safer than propofol?
Clinical studies indicate potential advantages in selected hemodynamic and recovery measures, but both drugs can cause respiratory and cardiovascular complications. Safety depends on patient characteristics, dose, monitoring and provider expertise.
Does remimazolam require flumazenil?
No. Flumazenil is not required for routine use. Its availability is a differentiating feature because it can reverse benzodiazepine effects when clinically indicated.
Can remimazolam replace midazolam in endoscopy?
It can compete with midazolam in endoscopy, but replacement depends on acquisition cost, procedural workflow, physician preference and local reimbursement. The strongest adoption case is in high-throughput centers that value predictable recovery.
What is the biggest investment risk for remimazolam?
The largest risk is a mismatch between clinical differentiation and hospital willingness to pay. If propofol and midazolam remain clinically acceptable at substantially lower cost, remimazolam may achieve volume growth without producing durable premium margins.
References
-
Doi, M., Morita, K., Takeda, J., Sakamoto, A., Yamakage, M., & Suzuki, T. (2021). Efficacy and safety of remimazolam versus propofol for general anesthesia: A multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. Journal of Anesthesiology, 35, 637-646.
-
Eagle Pharmaceuticals. (2022). Eagle Pharmaceuticals completes acquisition of Acacia Pharma. Eagle Pharmaceuticals.
-
PAION AG. (2024). Corporate and insolvency announcements. PAION AG.
-
Pastis, N. J., Yarmus, L. B., Schippers, F., Ost, D. E., Chen, A., Feller-Kopman, D., Wahidi, M. M., Shojaee, S., Kheir, F., & Murgu, S. (2019). Safety and efficacy of remimazolam compared with placebo and midazolam for moderate sedation during bronchoscopy. Chest, 155(1), 137-146.
-
U.S. Food and Drug Administration. (2020). FDA approves Byfavo for procedural sedation in adults. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
